News | Patient Positioning Radiation Therapy | September 22, 2017

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

Series of poster presentations, late-breakers and panel discussions will examine clinical and quality of life benefits of novel absorbable hydrogel spacing technology for prostate cancer treatment

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

September 22, 2017 — Augmenix Inc. announced a preview of clinical data that will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2017), Sept. 24-27 in San Diego. The presentations will provide new insights on the clinical and quality of life benefits of the company’s novel absorbable hydrogel spacing technology in providing protection during radiation therapy.

SpaceOAR hydrogel, Augmenix’s lead product, is U.S. Food and Drug Administration (FDA)-cleared and is designed to protect the rectum in men undergoing radiation therapy for prostate cancer.

Most notably at ASTRO 2017, results from the first prospective study evaluating the efficacy of SpaceOAR hydrogel in patients undergoing high-dose stereotactic body radiation therapy (SBRT) for prostate cancer will be presented as a late-breaking clinical trial on Tuesday, Sept. 26. Additionally, the first five-year quality of life data results in prostate cancer patients treated with SpaceOAR hydrogel will unveiled the same day in an oral presentation, demonstrating significant bowel and sexual function benefits. A didactic industry-sponsored panel discussion on the present and future role of hydrogel spacing in the treatment of prostate cancer, led by renowned radiation oncologists from around the world, will occur on Monday, Sept. 25.

Following is a detailed schedule of the company’s events in chronological order (times are U.S. Pacific Daylight Time):

Sunday, September 24

The following poster presentations will take place from 1:15 p.m. – 2:45 p.m. in the Poster Hall:

  • Poster Presentation (No : 2559): Dosimetry for Organs at Risk With and Without Use of Perirectal Hydrogel Spacer in Prostate Cancer Patients Treated With SBRT
    • Presented by: Daniel B. Fried, M.D., Ph.D., MPH
  • Poster Presentation (No : 2572): A Pilot Study – The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy
    • Presented by Huong Ho, DO
  • Poster Presentation (No : 3383): Updated Retrospective Dose Volume Histogram Analysis of High Dose Rate Prostate Brachytherapy Patients With Hydrogel Spacer Implantation
    • Presented by Sean Cavanaugh, M.D.

 

Monday, September 25

  • Industry-Expert Theatre: Present and Future Role of Hydrogel Spacing in the Treatment of Prostate Cancer – 3 & 5 Year QOL Evidence and Stereotactic Body Radiation Therapy (SBRT) Experience
    • Time/Location: 12:30 p.m. – 1:30 p.m. Exhibit Hall – Theatre 1
    • Speakers: Robert Timmerman, M.D., professor of radiation oncology and neurology at the University of Texas Southwestern Medical Center in Dallas; Michael Zelefsky, M.D., professor of radiation oncology, vice-chair of the Department of Radiology and chief of the Brachytherapy Service at Memorial Sloan-Kettering Cancer Center in New York City; Daniel Hamstra, M.D., Ph.D., clinical director and professor at William Beaumont Oakland University Medical School, Department of Radiation Oncology, Beaumont Health, Dearborn, Mich.; and Prof. Dr. Michael Pinkawa, director of the Department of Radiation Oncology, MediClin Robert Janker Klinik in Bonn, Germany.
    • Moderator: Rodney Ellis, M.D., vice chair for clinical affairs at the University Hospitals Cleveland Medical Center and associate professor, radiation oncology at Case Western Reserve University in Cleveland.
  • Poster Presentation (No : 3613): The Rectal Dosimetric Effects of Perirectal Hydrogel Spacers in Men Undergoing Prostate Stereotactic Body Radiation Therapy (SBRT)
    • Time/Location: 4:15 p.m. – 5:45 p.m. Poster Hall
    • Presenter: Shaan Kataria, M.D.

Tuesday, September 26

  • Late-Breaking Abstracts Special Session (SS 22): Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer
    • Time/Location: 7:45 a.m. – 9 a.m. Room 5A
    • Presenter: Michael Folkert, M.D.
  • ePoster Presentation (No: 1083): Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results
    • Time/Location: 1:12 p.m. Room 5B
    • Presenter: Michael Pinkawa, M.D., Ph.D.
  • Poster Presentation (No : 2869): Biodegradable Hydrogel Spacer Injection for Contralateral Submandibular Gland Sparing in Radiation Therapy for Head and Neck Cancers
    • Time/Location: 2:45 p.m. – 4:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.
  • Poster Presentation (No : 2435): Novel Use of a Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum for Radiation Therapy for Pancreatic Cancer
    • Time/Location: 4:45 p.m. – 6:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.

Read "Augmenix Announces Positive Three-Year Long-Term Data for SpaceOAR Hydrogel Spacer"

For more information: www.augmenix.com

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...